Rischi per il feto legati alla somministrazione dei farmaci antiaritmici in gravidanza

Translated title of the contribution: Fetal risks related to the administration of antiarrhythmic drugs during pregnancy

Simone Ferrero, Barbara M. Colombo, Elisa Arena, Fabio Fenini, Nicola Ragni

Research output: Contribution to journalArticle

Abstract

The major concern about the administration of antiarrhythmic drugs during pregnancy is related to their effect on fetal well-being. Even if teratogenic risks are higher during organogenesis in the first 8 weeks of pregnancy, after this period undesirable effects may include depression of uterine blood flow, interference with fetal growth and development, and interference with labor and delivery. Most drugs are secreted in the mother's milk, a fact that raises concern about the nursing infants. In this report we review the fetal risks related to the management of maternal arrhythmias during pregnancy showing that most patients can be treated with an excellent result for their babies.

Translated title of the contributionFetal risks related to the administration of antiarrhythmic drugs during pregnancy
Original languageItalian
Pages (from-to)993-1002
Number of pages10
JournalItalian Heart Journal Supplement
Volume3
Issue number10
Publication statusPublished - Oct 2002

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Fetal risks related to the administration of antiarrhythmic drugs during pregnancy'. Together they form a unique fingerprint.

  • Cite this